Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer vaccines.

P Moingeon1

  • 1Aventis Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280, Marcy l'Etoile, France. philippe.moingeon@aventis.com

Vaccine
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Cancer vaccines have evolved from whole cell preparations to targeted tumor-associated antigens (TAAs). Current research focuses on improving safety and efficacy for better cancer immunotherapy outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Applications of artificial intelligence to new drug development].

Annales pharmaceutiques francaises·2021
Same author

Characterization of epitope specificities of reference antibodies used for the quantification of the birch pollen allergen Bet v 1.

Allergy·2017
Same author

Validation of ELISA methods for quantification of the major birch allergen Bet v 1 (BSP090).

Pharmeuropa bio & scientific notes·2017
Same author

Novel approaches and perspectives in allergen immunotherapy.

Allergy·2017
Same author

Enhancing Allergen-Presentation Platforms for Sublingual Immunotherapy.

The journal of allergy and clinical immunology. In practice·2017
Same author

The regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammation.

Mucosal immunology·2016
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Cancer vaccines have been tested in humans and animals, with early generations using whole cell preparations or tumor lysates.
  • These initial vaccines demonstrated the feasibility of cancer patient immunization and showed some clinical benefits in survival and recurrence rates.

Purpose of the Study:

  • To review the evolution of cancer vaccines from first-generation to second-generation approaches targeting tumor-associated antigens (TAAs).
  • To discuss the safety, immunogenicity, and potential clinical benefits of current cancer vaccine strategies.
  • To highlight future directions in cancer vaccine development, including targeting multiple TAAs and utilizing novel delivery platforms and adjuvants.

Main Methods:

  • Review of preclinical and clinical studies on cancer vaccines.

Related Experiment Videos

  • Analysis of data from first-generation (whole cell/lysate) and second-generation (TAA-targeted) vaccine trials.
  • Discussion of advances in understanding tumor immune escape mechanisms.

    • Main Results:

    • First-generation cancer vaccines proved feasibility and showed some clinical benefits.
    • Second-generation vaccines targeting TAAs are safe, eliciting immune responses without significant autoimmunity.
    • Understanding tumor immune escape mechanisms is crucial for future vaccine design.

    Conclusions:

    • Cancer vaccine development has progressed significantly, with current strategies demonstrating safety and immunogenicity.
    • Future cancer vaccines will likely involve multi-TAA targeting, advanced delivery systems, and combination therapies.
    • Development of tools to assess immune responses is critical for establishing correlates of clinical efficacy.